A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
Phenylketonuria (PKU) is a rare inherited condition where the body cannot properly break down an amino acid called phenylalanine (Phe), which is found in protein. People with PKU must usually stick to a very strict, low-protein diet to protect their brain health. This Phase 3 trial is testing a medicine called PTC923 (sepiapterin). The main goals are to check how safe it is to take over a longer period and to see if it helps the body process Phe more effectively. If successful, it could allow adults with PKU to eat more regular protein. Because this is an 'open-label' study, all participants will receive the active study medicine. Doctors will track side effects, run blood tests, and measure how much dietary protein participants can comfortably tolerate.
De un vistazo
¿De qué trata este estudio?
Phenylketonuria, often shortened to PKU, is a lifelong metabolic condition. People born with PKU lack enough of a working enzyme needed to process phenylalanine (Phe), a natural building block of protein found in foods like meat, fish, dairy, nuts, and even grains. Without strict management, Phe can build up to harmful levels in the blood and brain. Currently, managing PKU often means following a very demanding, low-protein diet and drinking special amino acid supplements every day.
This clinical trial is evaluating an experimental oral medicine called PTC923 (also known as sepiapterin). In the body, sepiapterin turns into a natural substance (BH4) that helps the missing or faulty enzyme work better. The hope is that PTC923 will help people with PKU break down Phe more easily, potentially allowing them to include more everyday protein in their meals.
This is a Phase 3 study, which is the final testing stage before a medicine can be approved for general prescription use. It is also an 'open-label' trial, meaning there is no dummy pill (placebo); everyone who takes part will be given the actual medicine.
Taking part in this research helps scientists understand whether PTC923 is safe over a longer period and whether it genuinely improves daily life and dietary freedom for people living with PKU.
Puntos clave
- Phase 3 trial assessing the safety and effectiveness of PTC923 (sepiapterin) for PKU.
- Aims to find out if the treatment allows people to safely eat more natural protein.
- Open to adults aged 18 and over diagnosed with phenylketonuria.
- Open-label study, meaning all participants receive the active medicine.
- Involves regular hospital check-ups, blood monitoring, and dietary assessments.
¿Quién puede ser elegible?
This study is open to adults aged 18 and older who have been diagnosed with phenylketonuria (PKU). Men and women are both eligible to join.
To take part, you must be able and willing to attend regular clinic appointments, take the study medicine as directed, and follow dietary instructions. This includes keeping track of what you eat during special food assessment periods.
People with certain other unstable health conditions, or those unable to attend regular hospital visits, may not be able to participate. Your PKU specialist or the trial team can confirm your full eligibility based on your medical history.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- I am aged 18 or older.
- I have a confirmed medical diagnosis of phenylketonuria (PKU).
- I am willing to take an experimental oral medication every day.
- I can attend regular clinic visits for blood tests and physical health checks.
- I am happy to complete food diaries and quality-of-life questionnaires.
¿En qué consiste la participación?
Taking part in this study involves taking the study medicine (PTC923) by mouth. You will visit a specialist hospital clinic regularly so doctors can check your general health, record your blood pressure, carry out physical examinations, and take routine blood and urine samples.
A key part of the trial is a dietary assessment. The research team will carefully test how much Phe and natural protein you can safely consume while taking the medicine. You will also be asked to complete short quality-of-life questionnaires to share how you feel day to day and how manageable the treatment is. The trial team will support you throughout the entire study period, which will be explained in detail before you decide to join.
Riesgos y beneficios potenciales
Locations (10)
- —No verificadoPaíses Bajos
- —No verificadoAlemania
- —No verificadoEspaña
- —No verificadoItalia
- —No verificadoDinamarca
- —No verificadoPortugal
- —No verificadoPolonia
- —No verificadoChequia
- —No verificadoFrancia
- —No verificadoEslovenia
Preguntas comunes
What is the main goal of this trial?
The study aims to check the long-term safety of PTC923 and see if it helps adults with PKU tolerate more protein in their everyday diet.
Will I definitely receive the real medicine?
Yes. This is an open-label trial, so there is no placebo (dummy medicine). All participants receive PTC923.
Do I have to change my diet immediately?
No. Any dietary changes or protein increases will be carefully guided and monitored step-by-step by the trial's metabolic dietitians.
¿Puedo abandonar el estudio si cambio de opinión?
Yes. You have the right to withdraw from the trial at any time, for any reason, and your normal medical care will continue as usual.
Does taking part cost anything?
No. The study medication and all trial-related tests are provided free of charge, and travel expenses to clinic visits are usually reimbursed.
Cómo obtener más información
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.